dulaglutide · Trulicity

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes, Atherosclerotic Cardiovascular Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Trulicity Subcutaneous Injection 0.75 mg Ateos, type 2 diabetes mellitus
Product first approved 2015pj.jiho.jp
EU
  • Type 2 diabetes mellitus in patients 10 years and above, monotherapy or add-on
Product first approved 2014EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (25)
Type 2 Diabetes
NCT06739122 · Eli Lilly and Company
2025-01-10 – 2027-12 · Type 2 Diabetes
What this study did
NCT06235086 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2024-04-08 – 2026-02-03 · Type 2 Diabetes Mellitus
What this study did
NCT04255433 · Eli Lilly and Company
2020-05-29 – 2025-06-12 · Type 2 Diabetes Mellitus
What this study did
NCT05606913 · Innovent Biologics (Suzhou) Co. Ltd.
2023-01-06 – 2024-04-09 · Type 2 Diabetes
What this study did
NCT04809220 · Eli Lilly and Company
2021-04-13 – 2023-04-26 · Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Hypoglycemic Agents, Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT04591626 · Eli Lilly and Company
2020-12-07 – 2022-04-28 · Type 2 Diabetes Mellitus
What this study did
NCT02597049 · Eli Lilly and Company
2015-11 – 2017-02 · Type 2 Diabetes Mellitus
What this study did
NCT02152371 · Eli Lilly and Company
2014-05 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01769378 · Eli Lilly and Company
2013-01 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01648582 · Eli Lilly and Company
2012-07 – 2014-12 · Type 2 Diabetes Mellitus
What this study did
NCT01644500 · Eli Lilly and Company
2012-07 – 2014-08 · Type 2 Diabetes Mellitus
What this study did
NCT01558271 · Eli Lilly and Company
2012-03 – 2014-05 · Type 2 Diabetes Mellitus
What this study did
NCT01468181 · Eli Lilly and Company
2011-11 – 2013-12 · Type 2 Diabetes Mellitus
What this study did
NCT01624259 · Eli Lilly and Company
2012-06 – 2013-11 · Type 2 Diabetes
What this study did
NCT01075282 · Eli Lilly and Company
2010-02 – 2012-11 · Diabetes Mellitus, Type 2
What this study did
NCT01191268 · Eli Lilly and Company
2010-11 – 2012-09 · Diabetes Mellitus, Type 2
What this study did
NCT01126580 · Eli Lilly and Company
2010-05 – 2012-06 · Diabetes Mellitus, Type 2
What this study did
NCT01064687 · Eli Lilly and Company
2010-02 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07834398 · Zagazig University
2025-11-14 – 2026-04-21 · Non-diabetec Obesity, Obesity (Disorder)
What this study did
NCT07820111 · Zagazig University
2025-10-18 – 2026-03-17 · Obese Diabetics, Obese Non Diabetic
What this study did
Phase 2/3 (2)
Atherosclerotic Cardiovascular Disease
NCT07282041 · National University of Singapore
2025-12-17 – 2030-12-01 · Intracranial Atherosclerosis, Stroke, Ischemic
What this study did
Type 2 Diabetes
NCT00734474 · Eli Lilly and Company
2008-08 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (15)
Type 2 Diabetes
NCT06148649 · Dongguan HEC Biopharmaceutical R&D Co., Ltd.
2023-12-10 – 2025-04-23 · Type 2 Diabetes
What this study did
NCT02973100 · Eli Lilly and Company
2016-12 – 2017-08-14 · Type 2 Diabetes
What this study did
NCT01149421 · Eli Lilly and Company
2010-06 – 2012-01 · Diabetes Mellitus, Type 2
What this study did
NCT01001104 · Eli Lilly and Company
2009-10 – 2010-12 · Diabetes Mellitus, Type 2
What this study did
NCT00791479 · Eli Lilly and Company
2008-12 – 2010-01 · Diabetes Mellitus, Type 2
What this study did
NCT00630825 · Eli Lilly and Company
2008-04 – 2009-01 · Diabetes Mellitus Type 2
What this study did
Other / comorbidity
NCT05478707 · AdventHealth Translational Research Institute
2023-10-05 – 2028-07-30 · Diabetes Mellitus, Type 1, Endothelial Dysfunction
What this study did
NCT04731272 · University of Pennsylvania
2021-07-16 – 2028-06-30 · Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
What this study did
NCT07370922 · Ain Shams University
2024-11-22 – 2026-01-05 · Transfusion Dependent Beta Thalassemia
What this study did
NCT05254418 · Vanderbilt University Medical Center
2022-03-15 – 2024-08-01 · Chronic Kidney Diseases
What this study did
NCT04687514 · University Hospital, Basel, Switzerland
2021-05-05 – 2022-09-05 · Sexual Functioning
What this study did
NCT03204396 · University Hospital, Basel, Switzerland
2017-06-26 – 2022-08-30 · Glucagon-like Peptide-1, Smoking Cessation, Weight Change, Body, Craving
What this study did
NCT03668470 · Hospices Civils de Lyon
2019-01-31 – 2021-02-03 · Adult Subjects With Type1Diabetes and Insulin Microsecretion
What this study did
NCT02770885 · University Hospital, Basel, Switzerland
2016-03 – 2019-10-07 · Primary Polydipsia
What this study did
NCT03141632 · University Hospital, Basel, Switzerland
2016-10-17 – 2017-05-12 · Thirst, Water-Electrolyte Imbalance
What this study did
Phase 1/2 (2)
Type 2 Diabetes
NCT04466904 · Innovent Biologics (Suzhou) Co. Ltd.
2020-09-12 – 2021-05-28 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT07319286 · Ain Shams University
2025-08-04 – 2027-03 · Menstrual Irregularities, Type1 Diabetes Mellitus, Glucagon-Like Peptide-1 Receptor Agonists, Female Reproductive Health
What this study did
Phase 1 (17)
Type 2 Diabetes
NCT07313813 · Eli Lilly and Company
2025-12-29 – 2026-08-13 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT05407961 · Eli Lilly and Company
2022-06-07 – 2024-01-12 · Diabetes Mellitus, Type 2
What this study did
NCT05377333 · Eli Lilly and Company
2022-06-02 – 2023-11-22 · Diabetes Mellitus, Type 2
What this study did
NCT04641312 · Eli Lilly and Company
2020-11-25 – 2021-12-21 · Healthy, Type 2 Diabetes
What this study did
NCT01667900 · Eli Lilly and Company
2012-08 – 2014-06 · Diabetes Mellitus, Type 2, Healthy Volunteers
What this study did
NCT01524770 · Eli Lilly and Company
2012-03 – 2012-06 · Diabetes Mellitus, Type 2
What this study did
NCT01408888 · Eli Lilly and Company
2011-08 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01458210 · Eli Lilly and Company
2011-10 – 2012-02 · Diabetes Mellitus, Type 2
What this study did
NCT01432938 · Eli Lilly and Company
2011-09 – 2011-12 · Diabetes Mellitus, Type 2
What this study did
NCT01253304 · Eli Lilly and Company
2010-11 – 2011-11 · Diabetes Mellitus, Type 2
What this study did
NCT01436201 · Eli Lilly and Company
2011-09 – 2011-11 · Diabetes Mellitus, Type 2
What this study did
NCT01324388 · Eli Lilly and Company
2011-03 – 2011-08 · Diabetes Mellitus, Type 2
What this study did
NCT01300260 · Eli Lilly and Company
2011-02 – 2011-08 · Diabetes Mellitus, Type 2
What this study did
NCT01301092 · Eli Lilly and Company
2011-02 – 2011-08 · Diabetes Mellitus, Type II
What this study did
NCT01215968 · Eli Lilly and Company
2010-09 – 2011-07 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT03363906 · Eli Lilly and Company
2017-12-07 – 2018-06-06 · Healthy
What this study did
NCT01250834 · Eli Lilly and Company
2010-12 – 2011-03 · Healthy Volunteers
What this study did
Phase 4 (17)
Type 2 Diabetes
NCT07537088 · First Affiliated Hospital of Wannan Medical College
2026-05 – 2027-07 · T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT05140694 · Seoul National University Bundang Hospital
2023-12-01 – 2025-12-31 · Metabolic-associated Fatty Liver Disease, Type 2 Diabetes
What this study did
NCT03648554 · Central Hospital, Nancy, France
2019-09-01 – 2024-03-30 · Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
What this study did
NCT05659537 · Eli Lilly and Company
2022-12-29 – 2024-01-16 · Diabetes Mellitus, Type 2
What this study did
NCT04893148 · Chungbuk National University Hospital
2020-05-26 – 2022-12-30 · Type 2 Diabetes Mellitus, Glucose, High Blood
What this study did
NCT03444142 · University of Guadalajara
2017-11-17 – 2021-11-30 · Diabetes Mellitus, Type 2
What this study did
NCT04189848 · Novo Nordisk A/S
2019-12-03 – 2020-02-27 · Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
What this study did
NCT03724981 · Eli Lilly and Company
2018-10-18 – 2019-04-12 · Diabetes Mellitus, Type 2
What this study did
NCT02750410 · Eli Lilly and Company
2016-08 – 2018-06-18 · Type 2 Diabetes
What this study did
NCT03315780 · Eli Lilly and Company
2017-10-28 – 2018-02-28 · Type 2 Diabetes
What this study did
Other / comorbidity
NCT06324461 · The University of Hong Kong
2024-03-20 – 2028-12-31 · Myocardial Injury
What this study did
NCT05218915 · Elaine Chow
2022-01-28 – 2024-10-30 · Diabetes Mellitus, Diabetic Kidney Disease
What this study did
NCT04387201 · The University of Texas Health Science Center, Houston
2020-05-15 – 2023-10-06 · Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
What this study did
NCT04862234 · Emory University
2021-08-06 – 2023-06-22 · Hyperglycemia Stress
What this study did
NCT03743025 · Emory University
2019-03-08 – 2023-05-02 · Stress Hyperglycemia
What this study did
NCT03824002 · University of Palermo
2017-04-01 – 2018-04-20 · Diabetes Mellitus
What this study did
Early phase / not applicable (5)
Type 2 Diabetes
NCT06611904 · Attikon Hospital
2018-02-01 – 2024-12-15 · Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness
What this study did
NCT04829903 · Corporacion Parc Tauli
2020-01-02 – 2021-11-20 · Type 2 Diabetes Treated With Insulin, Obesity, Adolescent Obesity
What this study did
NCT03590626 · Medanta, The Medicity, India
2019-01-01 – 2020-02-18 · Non Alcoholic Fatty Liver Disease, Type2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06331286 · First Affiliated Hospital of Zhejiang University
2023-09-01 – 2024-12-31 · Bipolar Disorder, Obesity, Cognition
What this study did
NCT06182891 · The Affiliated Hospital of Xuzhou Medical University
2021-10-30 – 2023-10-30 · Type 2 Diabetic Nephropathy
What this study did
Used as active comparator (24)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (9)
Type 2 Diabetes
NCT07668336 · Eli Lilly and Company
2026-07-08 – 2030-03 · Diabetes Mellitus, Type 2
What this study did
NCT07156539 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-09-30 – 2027-05-30 · Type 2 Diabetes
What this study did
NCT06257966 · Beijing Dongfang Biotech Co., Ltd.
2024-07-17 – 2026-11-30 · Type2 Diabetes Mellitus
What this study did
NCT05680129 · Hangzhou Sciwind Biosciences Co., Ltd.
2023-01-10 – 2024-10-12 · T2DM, Type 2 Diabetes Mellitus
What this study did
NCT03861052 · Eli Lilly and Company
2019-05-07 – 2021-03-31 · Type 2 Diabetes
What this study did
NCT03684642 · Sanofi
2018-09-26 – 2020-11-17 · Type 2 Diabetes Mellitus
What this study did
NCT03015220 · Novo Nordisk A/S
2017-01-10 – 2018-07-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02648204 · Novo Nordisk A/S
2016-01-06 – 2017-05-19 · Diabetes, Diabetes Mellitus, Type 2
What this study did
Phase 2 (8)
Type 2 Diabetes
NCT07677891 · ProGen. Co., Ltd.
2026-10 – 2027-06 · Type 2 Diabetes
What this study did
NCT07109700 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-04-30 – 2026-02-28 · Type 2 Diabetes
What this study did
NCT06901648 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-02-06 – 2025-04-09 · Type 2 Diabetes
What this study did
NCT05348122 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2022-06-15 – 2023-11-01 · Type 2 Diabetes Mellitus
What this study did
NCT04867785 · Eli Lilly and Company
2021-05-13 – 2022-10-27 · Type 2 Diabetes
What this study did
NCT05048719 · Eli Lilly and Company
2021-09-15 – 2022-09-30 · Type 2 Diabetes
What this study did
NCT04965506 · Innovent Biologics (Suzhou) Co. Ltd.
2021-09-06 – 2022-06-11 · Type 2 Diabetes
What this study did
NCT03131687 · Eli Lilly and Company
2017-05-24 – 2018-08-01 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (5)
Type 2 Diabetes
NCT05516966 · Fujian Shengdi Pharmaceutical Co., Ltd.
2022-10-12 – 2023-05-24 · Diabetes Mellitus, Type 2
What this study did
NCT05459285 · Sunshine Lake Pharma Co., Ltd.
2022-05-31 – 2022-07-08 · Type 2 Diabetes
What this study did
NCT04515576 · Eli Lilly and Company
2020-08-25 – 2021-03-09 · Diabetes Mellitus, Type 2
What this study did
NCT04143802 · Eli Lilly and Company
2019-12-18 – 2020-12-28 · Diabetes Mellitus, Type 2
What this study did
NCT02759107 · Eli Lilly and Company
2016-05-11 – 2017-06-26 · Healthy, Type 2 Diabetes Mellitus (T2DM)
What this study did
Phase 4 (2)
Type 2 Diabetes
NCT05564039 · Eli Lilly and Company
2022-11-30 – 2024-08-12 · Type 2 Diabetes
What this study did
NCT05005741 · Second Xiangya Hospital of Central South University
2021-05-01 – 2023-12-31 · Diabetes Mellitus, Type 2, Overweight or Obesity
What this study did

Competitive landscape

This mechanism is crowded: 50 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dulaglutide (Trulicity): this drugApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Saxenda)
Approved(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy Tablets)
Approved(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Sitagliptin (Januvia)ApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
HenagliflozinPhase 3Small moleculeSodium-glucose cotransporter 2 (SGLT2)Reliable signal
NCT04390295: Placebo-adjusted LS mean HbA1c change at Week 24: -0.76% (5 mg) and -0.80% (10 mg) vs placebo, both P < .0001.
NCT03159052: Placebo-adjusted LS mean HbA1c change at Week 24: -0.91% (5 mg) and -0.94% (10 mg) vs placebo, both P < .001.
HR17031Phase 3PeptideInsulin receptor / GLP-1 receptor (combination)Partial signal
NCT06881264: Week 26 HbA1c change, LS mean: HR17031 -1.85% vs insulin glargine -1.06% (sponsor-reported)
NCT06871761: HbA1c change from baseline at week 26: HR17031 -1.53% vs insulin glargine -0.25%; LS-mean difference -1.29% (95% CI -1.48 to -1.10), P<0.0001 (sponsor-reported, ADA 2026)
IcoSema (Kyinsu)Phase 3PeptideInsulin receptor (basal), GLP-1 receptorPartial signal
NCT06269107: (-3·32 vs -2·44 percentage points; estimated treatment difference [ETD] -0·88 percentage points [95% CI -1·12 to -0·63]), confirming superiority of IcoSema (p<0·001)
NCT05352815: Change in Glycated Haemoglobin (HbA1c) (Baseline (Week 0), Week 52): IcoSema -1.6 Percentage point of HbA1c (Standard Deviation 0.99) vs Insulin Icodec -0.9 Percentage point of HbA1c (Standard Deviation 1.01)
Insulin Sudelidec (INS068)Phase 3PeptideInsulin receptor (basal)Partial signal
NCT05699408: Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%)
NCT05702073: Change in HbA1c at Week 26 (Study 301, basal-insulin background, n=423): insulin sudelidec (INS068) -0.70% vs insulin glargine -0.83%; between-group difference 0.13% (95% CI -0.05% to 0.31%)
Janagliflozin (Huiyoujing)Phase 3Small moleculeSGLT2Reliable signal
NCT03811548: Placebo-adjusted HbA1c change at week 24: janagliflozin 25 mg -0.80% (95% CI -0.98 to -0.62), 50 mg -0.88% (95% CI -1.06 to -0.70); P<0.001 for both (Ji et al., Diabetes Obes Metab 2023)
JW0201Phase 3Small moleculeDipeptidyl peptidase-4 (DPP-4)Partial signal
NCT05814393: HbA1c change from baseline at Week 24: -0.83% with JW0201 (anagliptin) add-on vs -0.03% with placebo; between-group difference -0.80 percentage points (95% CI -0.95 to -0.64; P<0.0001)
Lobeglitazone (Duvie)Phase 3Small moleculePPAR-gammaWeak signal
NCT03739125: HbA1c change at 24 weeks vs placebo (Study 1, empagliflozin 10 mg plus metformin background): -0.71% (95% CI -0.88 to -0.55), p<0.001. The publication reports Study 2 (empagliflozin 25 mg background, NCT03627182) separately.
NCT01106131: HbA1c change at week 24: -0.74% lobeglitazone vs -0.74% pioglitazone (difference 0.01%, 95% CI -0.16 to 0.18); noninferior.
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signalNo reviewed efficacy summary in this indication
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05606913: HbA1c change from baseline at Week 28: -1.61 percentage points (mazdutide 4mg) and -1.66 percentage points (mazdutide 6mg) vs -1.36 percentage points (dulaglutide 1.5mg); superiority P<.01 for both doses.
NCT05628311: HbA1c change from baseline at week 24: -1.57% (mazdutide 4mg), -2.15% (mazdutide 6mg) vs -0.14% (placebo); mazdutide superior to placebo
MDR-001
Phase 3(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Mitiglinide (Glufast)Phase 3Small moleculeSUR1 (short-acting)Partial signal
NCT01037842: Change in HbA1c from randomization to Week 16 endpoint: metformin+mitiglinide -0.7% (SD 0.6) vs metformin+placebo -0.4% (SD 0.7); difference significant at P=0.002.
NCT00461617: Change in HbA1c from baseline: mitiglinide -0.53% (wk12) / -0.77% (wk20) vs nateglinide -0.58% (wk12) / -0.71% (wk20); intergroup difference 0.05% (95% CI -0.19 to 0.30) at week 12 and 0.06% (95% CI -0.31 to 0.19) at week 20.
NoiiglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ObicetrapibPhase 3Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Pegloxenatide (Fulaimei)Phase 3PeptideGLP-1 receptorReliable signal
NCT02477969: Phase 3b add-on-to-metformin trial: proportion achieving HbA1c <7.0% at week 24 was 37.4% (100μg) and 40.6% (200μg) vs 16.8% (placebo).
NCT02477865: Phase 3a monotherapy trial: HbA1c LS-mean change at week 24 was -1.02% (100μg) and -1.34% (200μg) vs -0.17% (placebo), p<0.0001.
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT06354660: Change in HbA1c from baseline (7.9%) at Week 40: 4 mg -1.7%, 9 mg -2.0%, 12 mg -1.9%, placebo -0.8%; retatrutide met the primary endpoint.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06650007: Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo
NCT06649344: Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06589765: Primary, HbA1c change from baseline at week 32 vs dapagliflozin 10 mg (non-inferiority margin 0.4%, primary non-inferiority estimand): 30 mg -0.30% (95% CI -0.51 to -0.09), 60 mg -0.22% (95% CI -0.44 to -0.01), 90 mg -0.40% (95% CI -0.62 to -0.19); non-inferiority met for all three doses (all P<0.0001). Superiority (treatment policy estimand): 90 mg -0.25% (95% CI -0.45 to -0.05; one-sided P=0.0067), 60 mg not significant (P=0.0789).
NCT06672172: OUTSTAND-1 phase 3 T2D trial (placebo-controlled, diet-and-exercise inadequately controlled); enrollment (284) matches this listing exactly. Primary endpoint (HbA1c reduction at Week 32 vs placebo, across 30/60/90mg doses) was met: 1.40-1.68% reduction vs 0.06% for placebo.
Visepegenatide (PB-119)Phase 3PeptideGLP-1 receptorReliable signal
NCT04504396: Change in HbA1c from baseline: -1.25% (95% CI -1.35 to -1.16) with visepegenatide (PB-119) vs -0.68% (95% CI -0.78 to -0.59) with placebo; treatment difference -0.57% (95% CI -0.71 to -0.43), p<0.001.
NCT04504370: LSM change in HbA1c from baseline to week 24: visepegenatide (PB-119) -1.36% (95% CI -1.52 to -1.20) vs placebo -0.63% (95% CI -0.79 to -0.46); treatment difference -0.73% (95% CI -0.96 to -0.50, p<0.001)
Zovaglutide
Phase 3(overall)
PeptideGLP-1 receptor
Reliable signal(overall)
No reviewed efficacy summary in this indication
DA-302168SPhase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Exenatide (PT320)
Phase 2(overall)
PeptideGLP-1 receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Regor GLP-1Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SAL0150Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
TE-8105
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
TifeglipronPhase 2Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
TTP273Phase 2Small moleculeGLP-1 receptorReliable signal
NCT02653599: Change in HbA1c from baseline at Week 12: placebo-subtracted difference -0.86 percentage points (TTP273 150 mg once daily) and -0.71 percentage points (TTP273 150 mg twice daily); placebo arm HbA1c increased 0.15 percentage points from baseline; described as a statistically significant reduction.
UtreglutidePhase 2PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ZT006
Phase 2(overall)
PeptideGLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
BMF-650
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
DehydraTECH-CBD / Semaglutide
Phase 1(overall)
CombinationOral peptide delivery platform, GLP-1 receptor
Weak signal(overall)
No reviewed efficacy summary in this indication
IBI3032
Phase 1(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Liraglutide (HUC2-676)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08642534
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
PF-08656795
Phase 1(overall)
UndisclosedGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Semaglutide (DWRX5003)
Phase 1(overall)
PeptideGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
XW014Phase 1Small moleculeGLP-1 receptorWeak signalNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Large race: only the 111 furthest-along competitors are listed; 55 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trulicity (dulaglutide) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1/2Menstrual Irregularities, Type1 Diabetes Mellitus, Glucagon-Like Peptide-1 Receptor Agonists, Female Reproductive HealthEnrolling by invitation
Est. primary completion 2026-12 · NCT07319286 · CT.gov ↗
What to watch
2027 (3)
April 2027 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2027-04 · NCT07537088 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, DiabetesRecruiting
Est. primary completion 2027-06-30 · NCT04731272 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Type 2 DiabetesRecruiting
Est. primary completion 2027-12 · NCT06739122 · CT.gov ↗
What to watch
2028 (2)
June 2028 (1)
Phase 2Diabetes Mellitus, Type 1, Endothelial DysfunctionRecruiting
Est. primary completion 2028-06-30 · NCT05478707 · CT.gov ↗
What to watch
December 2028 (1)
Phase 4Myocardial InjuryRecruiting
Est. primary completion 2028-12-31 · NCT06324461 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2/3Atherosclerotic Cardiovascular DiseaseRecruiting
Est. primary completion 2030-12-01 · NCT07282041 · CT.gov ↗
What to watch

See the full readout calendar ↗